Quick Answer
Kura Oncology, Inc. reported Total Revenue of $67.48 million for fiscal year 2025.
Kura Oncology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $67.48M +25.2% |
$53.88M | $0.00 | — | — | — |
| Revenue (ASC 606) | $67.48M +25.2% |
$53.88M | $0.00 | — | — | — |
| Net Income | -$278.67M -60.2% |
-$173.98M -14.0% |
-$152.63M -12.4% |
-$135.84M -4.1% |
-$130.47M -45.6% |
-$89.62M -41.9% |
| Diluted EPS | -$3.18 -57.4% |
-$2.02 +2.9% |
-$2.08 -2.5% |
-$2.03 -3.0% |
-$1.97 -16.6% |
-$1.69 |
| Total Assets | $738.36M -2.9% |
$760.16M +69.3% |
$448.94M -1.6% |
$456.31M -14.6% |
$534.05M -17.5% |
$647.21M +167.5% |
| Cash and Equivalents | $149.10M -33.6% |
$224.46M +501.5% |
$37.32M -28.0% |
$51.80M -42.9% |
$90.67M -72.1% |
$325.49M +1145.4% |
| Long-Term Debt | $9.71M +40.4% |
$6.92M -25.9% |
$9.33M +1.9% |
$9.16M | — | $4.25M -41.4% |
| Stockholders Equity | $174.13M -57.9% |
$413.64M +4.1% |
$397.27M -5.5% |
$420.28M -17.0% |
$506.61M -17.1% |
$610.90M +179.2% |
| R&D Expense | $251.07M +47.7% |
$169.97M +47.5% |
$115.23M +24.2% |
$92.81M +9.6% |
$84.72M +40.3% |
$60.40M +26.3% |
| Operating Income | -$303.63M -57.2% |
-$193.19M -16.5% |
-$165.80M -18.5% |
-$139.87M | — | — |
| Shares Outstanding | 87.86M +12.3% |
78.23M +5.2% |
74.35M +8.8% |
68.31M +2.6% |
66.57M +0.6% |
66.19M +45.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $20.75M | — | +35.7% |
| Revenue (ASC 606) | September 30, 2025 | $20.75M | — | +35.7% |
| Net Income | September 30, 2025 | -$74.12M | -36.2% | -12.1% |
| Diluted EPS | September 30, 2025 | -$0.85 | -34.9% | -13.3% |
| Total Assets | September 30, 2025 | $649.38M | +35.6% | -4.8% |
| Cash and Equivalents | September 30, 2025 | $95.29M | +92.6% | +16.3% |
| Long-Term Debt | September 30, 2025 | $5.34M | -31.2% | -18.0% |
| Stockholders Equity | September 30, 2025 | $242.54M | -42.8% | -20.6% |
| R&D Expense | September 30, 2025 | $67.91M | +62.8% | +8.2% |
| Operating Income | September 30, 2025 | -$80.00M | -33.6% | -10.1% |
| Shares Outstanding | September 30, 2025 | 87.02M | +11.9% | +0.3% |
- Kura Oncology, Inc. reported Total Revenue of $67.48 million for fiscal year 2025.
- Kura Oncology, Inc. showed an increase of +25.2% in Total Revenue compared to the prior fiscal year.
- Kura Oncology, Inc. reported Revenue (ASC 606) of $67.48 million for fiscal year 2025.
- Kura Oncology, Inc. showed an increase of +25.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Kura Oncology, Inc. reported Net Income of -$278.67 million for fiscal year 2025.
- Kura Oncology, Inc. showed a decrease of -60.2% in Net Income compared to the prior fiscal year.
- Kura Oncology, Inc. reported Diluted EPS of $3.18 per share (loss) for fiscal year 2025.
- Kura Oncology, Inc. showed a decrease of -57.4% in Diluted EPS compared to the prior fiscal year.
- Kura Oncology, Inc. reported Total Assets of $738.36 million for fiscal year 2025.
- Kura Oncology, Inc. showed a decrease of -2.9% in Total Assets compared to the prior fiscal year.
- Kura Oncology, Inc. reported Cash and Equivalents of $149.10 million for fiscal year 2025.
- Kura Oncology, Inc. showed a decrease of -33.6% in Cash and Equivalents compared to the prior fiscal year.
- Kura Oncology, Inc. reported Long-Term Debt of $9.71 million for fiscal year 2025.
- Kura Oncology, Inc. showed an increase of +40.4% in Long-Term Debt compared to the prior fiscal year.
- Kura Oncology, Inc. reported Stockholders Equity of $174.13 million for fiscal year 2025.
- Kura Oncology, Inc. showed a decrease of -57.9% in Stockholders Equity compared to the prior fiscal year.
- Kura Oncology, Inc. reported R&D Expense of $251.07 million for fiscal year 2025.
- Kura Oncology, Inc. showed an increase of +47.7% in R&D Expense compared to the prior fiscal year.
- Kura Oncology, Inc. reported Operating Income of -$303.63 million for fiscal year 2025.
- Kura Oncology, Inc. showed a decrease of -57.2% in Operating Income compared to the prior fiscal year.
- Kura Oncology, Inc. reported Shares Outstanding of 87.86 million shares for fiscal year 2025.
- Kura Oncology, Inc. showed an increase of +12.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: